| Policies for biosimilar uptake in Europe: an overview E Moorkens, AG Vulto, I Huys, P Dylst, B Godman, S Keuerleber, B Claus, ... PloS one 12 (12), e0190147, 2017 | 252 | 2017 |
| The implementation of managed entry agreements in Central and Eastern Europe: findings and implications A Ferrario, D Arāja, T Bochenek, T Čatić, D Dankó, M Dimitrova, J Fürst, ... Pharmacoeconomics 35, 1271-1285, 2017 | 167 | 2017 |
| The Expiry of Humira® Market Exclusivity and the Entry of Adalimumab Biosimilars in Europe: An Overview of Pricing and National Policy Measures E Moorkens, B Godman, I Huys, I Hoxha, A Malaj, S Keuerleber, ... Frontiers in pharmacology 11, 591134, 2021 | 80 | 2021 |
| Pricing and reimbursement of biosimilars in Central and Eastern European countries P Kawalec, E Stawowczyk, T Tesar, J Skoupa, A Turcu-Stiolica, ... Frontiers in pharmacology 8, 288, 2017 | 80 | 2017 |
| Assessment of the expectancy, seriousness and severity of adverse drug reactions reported for chronic obstructive pulmonary disease therapy G Petrova, A Stoimenova, M Dimitrova, M Kamusheva, D Petrova, ... SAGE open medicine 5, 2050312117690404, 2017 | 55 | 2017 |
| Life expectancy and survival analysis of patients with diabetes compared to the non diabetic population in Bulgaria K Tachkov, K Mitov, Y Koleva, Z Mitkova, M Kamusheva, M Dimitrova, ... PloS one 15 (5), e0232815, 2020 | 51 | 2020 |
| Proposal for a regulation on health technology assessment in Europe–opinions of policy makers, payers and academics from the field of HTA P Vella Bonanno, A Bucsics, S Simoens, AP Martin, W Oortwijn, ... Expert review of pharmacoeconomics & outcomes research 19 (3), 251-261, 2019 | 51 | 2019 |
| Patient access, unmet medical need, expected benefits, and concerns related to the utilisation of biosimilars in Eastern European countries: a survey of experts A Inotai, M Csanadi, G Petrova, M Dimitrova, T Bochenek, T Tesar, K York, ... BioMed Research International 2018 (1), 9597362, 2018 | 43 | 2018 |
| Rationalizing the introduction and use of pharmaceutical products: The role of managed entry agreements in Central and Eastern European countries AM Rotar, A Preda, O Löblová, V Benkovic, S Zawodnik, L Gulacsi, ... Health Policy 122 (3), 230-236, 2018 | 33 | 2018 |
| Clinical characteristics, treatment patterns, and socio-economic burden of COPD in Bulgaria M Kamusheva, M Dimitrova, JFM van Boven, MJ Postma, T van der Molen, ... Journal of medical economics 20 (5), 503-509, 2017 | 24 | 2017 |
| Comparison of health-related quality-of-life measurement instruments in diabetic patients S Yordanova, V Petkova, G Petrova, M Dimitrov, E Naseva, M Dimitrova, ... Biotechnology & Biotechnological Equipment 28 (4), 769-774, 2014 | 24 | 2014 |
| New epidemiological, clinical and economic data for patients with acromegaly in Bulgaria M Kamusheva, S Vandeva, K Mitov, Y Rusenova, A Elenkova, ... Frontiers in Public Health 8, 147, 2020 | 21 | 2020 |
| Effect of education on patients with chronic obstructive pulmonary disease K Andreevska, V Petkova, S Jordanova, D Grekova, V Madjarov, ... World J Pharm Pharm Sci 3 (3), 01-09, 2013 | 17 | 2013 |
| Comparative analysis of the access to health-care services and breast cancer therapy in 10 Eastern European countries M Dimitrova, D Lakic, G Petrova, S Bešlija, J Culig SAGE open medicine 8, 2050312120922029, 2020 | 12 | 2020 |
| Cost of hospitalizations due to microvascular and macrovascular complications in type 1 and type 2 diabetic patients in Bulgaria M Dimitrova, M Doneva, V Valov, S Yordanova, M Manova, A Savova, ... Biotechnology & Biotechnological Equipment 29 (4), 805-813, 2015 | 12 | 2015 |
| Economic consequences of the vaccination against hepatitis A in the Bulgarian healthcare setting M Dimitrova, G Petrova, K Tachkov, MK Bozhkova, M Kamusheva, K Mitov Biotechnology & Biotechnological Equipment 28 (2), 366-371, 2014 | 9 | 2014 |
| Improved quality of diabetes control reduces complication costs in Bulgaria K Tachkov, K Mitov, Z Mitkova, M Kamusheva, M Dimitrova, V Petkova, ... Biotechnology & Biotechnological Equipment 33 (1), 814-820, 2019 | 7 | 2019 |
| Survival on pharmacotherapy analysis for patients after kidney transplantation SS Georgieva, KV Mitov, MN Dimitrova, G Petrova Int J Pharm Sci Rev Res 16 (2), 30-4, 2012 | 7 | 2012 |
| Economic consequences of the implementation of national screening program for chronic HCV infection M Dimitrova, K Tachkov, G Petrova Expert Review of Pharmacoeconomics & Outcomes Research 20 (4), 397-404, 2020 | 6 | 2020 |
| Humanistic and economic aspects of haemophilia treatment in Bulgaria. Comparison between two therapeutic approaches: prophylactic vs. on-demand treatment G Petrova, K Tachkov, S Georgieva, M Dimitrova Biotechnology & Biotechnological Equipment 28 (3), 576-582, 2014 | 6 | 2014 |
Guenka PetrovaProf. Pharmacoeconomic, Pharmaceutical Legislation, Medical University of Sofia, Faculty of PharmacyDirección de correo verificada de pharmfac.net
